Grifols (NASDAQ:GRFS) Stock Rating Cut to Strong Sell at Zacks Research

Zacks Research downgraded shares of Grifols (NASDAQ:GRFS) from a hold rating to a strong sell rating in a research report report published on Tuesday morning,Zacks reports.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Grifols from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. JPMorgan Chase & Co. reduced their price objective on shares of Grifols from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Monday, October 26th. Finally, Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, August 17th. One equities research analyst has rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Grifols presently has an average rating of “Sell” and an average target price of $9.00.

Grifols Trading Up 0.6%

NASDAQ:GRFS opened at $8.61 on Tuesday. The company has a market capitalization of $5.86 billion, a PE ratio of 45.32, a P/E/G ratio of 0.33 and a beta of 0.75. Grifols has a 52-week low of $6.96 and a 52-week high of $9.77. The stock’s 50 day moving average price is $7.62 and its 200 day moving average price is $8.00. The company has a quick ratio of 0.81, a current ratio of 2.33 and a debt-to-equity ratio of 1.05.

Institutional Investors Weigh In On Grifols

Several institutional investors have recently modified their holdings of GRFS. Commonwealth Equity Services LLC acquired a new position in Grifols during the third quarter worth $113,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Grifols in the third quarter valued at about $46,000. China Universal Asset Management Co. Ltd. grew its position in shares of Grifols by 14.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,259 shares of the biotechnology company’s stock valued at $162,000 after purchasing an additional 2,844 shares during the last quarter. Signaturefd LLC raised its position in shares of Grifols by 68.7% during the 3rd quarter. Signaturefd LLC now owns 4,372 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 1,781 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its position in shares of Grifols by 217.4% during the 3rd quarter. Quadrant Capital Group LLC now owns 35,155 shares of the biotechnology company’s stock worth $252,000 after purchasing an additional 24,080 shares during the last quarter.

Grifols Company Profile

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.